Aptamers Industry Overview
The global aptamers market size was valued at USD 1,624.5 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 23.5% from 2022 to 2030. Recent advancements in the generation, purification, and drug delivery for killing target cells have attracted the attention of many researchers towards aptamers due to the competitive advantages associated with them. Some of the advantages, including small molecular size, low immunogenicity, low cost of manufacturing, and lesser side effects compared to antibodies may fuel the R&D of novel aptamers, thereby driving the market growth.
Despite significant efforts, there are currently no highly effective treatments available against COVID-19 infections due to a large number of genetic mutations. However, biotechnological approaches appear to be promising in the treatment of COVID-19. Consequently, nucleic-acid-based aptamers and peptide aptamers might be effective in treating COVID-19 infection. Thus, various initiatives are being undertaken by governments to boost the R&D of novel treatments for COVID-19. For instance, in September 2020, the Department of Community and Economic Development awarded a contract of USD 320,000 to Aptagen LLC for the research and development of a novel treatment for the COVID-19.
Gather more insights about the market drivers, restraints, and growth of the Global Aptamers market
The aptamers-based diagnostic kits and assays developed by using SELEX technology have the ability to develop high-affinity neutralizers and bioprobes for monitoring SARS-CoV-2 and COVID-19 biomarkers. Therefore, the introduction of diagnostic kits in the market for disease diagnosis is projected to drive market growth. For instance, in December 2021, Achiko AG received approval from the Ministry of Health of the Republic of Indonesia for Aptamex, a COVID-19 diagnostic kit. AptameX is a second-generation diagnostic kit developed by using DNA aptamer-based technology that is a cost-effective, chemically synthesized and emerging diagnostic kit for healthcare.
Aptamers-based diagnostic products are the preferred choice among diagnostic and pathology labs for the diagnosis of disease at the cellular level due to their small size, high specificity, selectivity, and efficacy. Thus, the increasing prevalence of diseases such as cancer, CVD, and AMD may increase the footfall of patients in labs for the diagnosis of these diseases, consequently increasing the demand for aptamer-based diagnostic products. According to Cancer Research U.K. estimates, around 27.5 million people are expected to be diagnosed with cancer by 2040.
In March 2022, SomaLogic announced the initiation of assaying samples using SomaScan Assay for the European Prospective Investigation into Cancer and Nutrition (EPIC) study by analyzing 210 million protein measurements from 30,000 samples. This will help researchers in predicting cancer by better understanding its nature, which in turn may contribute to market growth by addressing the increased demand.
As of now, Macugen developed by Eyetech Pharmaceuticals, Inc., (currently commercialized by Bausch Health Companies Inc.) is the only U.S. FDA-approved (2004) therapeutic aptamer available on the market. It is used for the treatment of age-related muscular degeneration disorder (AMD). Technological advancements in research encourage scientists’ attention toward the development of novel aptamer-based therapeutic drugs for the treatment of various diseases. Currently, there are a number of products under different clinical trials including Zimura developed by IVERIC Bio, Inc., for the treatment of patients with AMD. Thus, the expected approval of this drug may boost the growth of the market over the forecast period.
Browse through Grand View Research's Pharmaceuticals Industry Research Reports.
Biomarkers Market - The global biomarkers market size was valued at USD 66.97 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 13.3% from 2023 to 2030.
Laboratory Developed Tests Market - The global laboratory developed tests market size was valued at USD 10.04 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 6.58% by 2030.
Aptamers Market Segmentation
Grand View Research has segmented the global aptamers market based on type, application, technology, end-user and region:
Aptamers Type Outlook (Revenue, USD Million, 2018 - 2030)
- Nucleic Acid Aptamers
- Peptide Aptamers
Aptamers Application Outlook (Revenue, USD Million, 2018 - 2030)
- Diagnostics
- Therapeutics
- Research And Developments
- Others
Aptamers Technology Outlook (Revenue, USD Million; 2018 - 2030)
- SELEX
- Other Technologies
Aptamers End-user Outlook (Revenue, USD Million; 2018 - 2030)
- Pharmaceutical & Biotechnology Companies
- Academic & Government Research Institutes
- CROs
Aptamers Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Market Share Insights
August 2021: ProAxsis Limited and Aptamer Group entered into a partnership for the development of optimer ligands for the diagnostic assays of ProAxsis. Optimer ligands are next-generation nucleic-acid-based affinity aptamers.
Key Companies profiled:
Some of the prominent players in the global aptamers market include:
- SomaLogic
- Aptamer Group
- Aptamer Sciences, Inc.
- Base Pair Biotechnologies
- Noxxon Pharma
- Vivonics Inc.
- Aptagen, LLC
- TriLink Biotechnologies
Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.
No comments:
Post a Comment